Download PDF
Exp Clin Endocrinol Diabetes 2013; 121(01): 6-13
DOI: 10.1055/s-0032-1327634
Article
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Vascular Endothelial Growth Factor – Marker for Proliferation in Thyroid Diseases?

P. Malkomes
1   Department of General Surgery, University Hospital of Frankfurt, Frankfurt, Germany
,
E. Oppermann
1   Department of General Surgery, University Hospital of Frankfurt, Frankfurt, Germany
,
W. O. Bechstein
1   Department of General Surgery, University Hospital of Frankfurt, Frankfurt, Germany
,
K. Holzer
1   Department of General Surgery, University Hospital of Frankfurt, Frankfurt, Germany
› Author Affiliations
Further Information

Publication History

received 20 April 2012
first decision 17 August 2012

accepted 24 September 2012

Publication Date:
17 January 2013 (online)

Also available at
   Permissions and Reprints

Abstract

Vascular endothelial growth factor (VEGF) is a critical regulator of angiogenesis and is involved in tumor development. To date, the role of VEGF in benign diseases of the thyroid is not well known. The purpose of the present study is to determine the expression of VEGF and its receptors in primary cultures of human thyrocytes.

Methods:

50 patients with uninodular (n=11), multinodular (n=15), recurrent goiter (n=14) and Graves’ disease (n=10) were enrolled. Nodular and corresponding paranodular tissue was obtained after surgery and investigated. RNA and protein were extracted from primary thyrocyte cultures. PCR, western blot and ELISA were performed to evaluate VEGF isoforms and VEGF receptor 1 and 2.

Results:

Significantly increased transcription and protein expression of VEGF and its receptors were detected in nodular tissue of uninodular and recurrent goiter compared to the corresponding normal tissue. Active secretion of VEGF by thyrocytes was confirmed by ELISA. In multinodu­lar goiter, no difference could be found between nodular and corresponding paranodular tissue in terms of expression of VEGF or its receptors. Furthermore, we found the highest levels of VEGF and its receptors in tissue obtained from patients with Graves’ disease.

Conclusion:

Increased expression of VEGF and its receptors might be crucial in the proliferation of thyrocytes and therefore may contribute to the development of goiter and goiter recurrence.

Key words

VEGF - VEGF receptors 1 and 2 - goiter - recurrent - multinodular - Graves’ disease
 

  • References

  • 1 Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161 (02) 851-858
    CrossrefPubMedGoogle Scholar
  • 2 Ferrara N, Houck K, Jakeman L et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13 (01) 18-32
    CrossrefPubMedGoogle Scholar
  • 3 Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25 (04) 581-611
    CrossrefPubMedGoogle Scholar
  • 4 Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18 (01) 4-25
    CrossrefPubMedGoogle Scholar
  • 5 Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005; 109 (03) 227-241
    CrossrefPubMedGoogle Scholar
  • 6 Kakeji Y, Koga T, Sumiyoshi Y et al. Clinical significance of vascular endothelial growth factor expression in gastric cancer. J Exp Clin Cancer Res 2002; 21 (01) 125-129
    PubMedGoogle Scholar
  • 7 Scott PA, Smith K, Poulsom R et al. Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-E4. Br J Cancer 1998; 77 (12) 2120-2128
    CrossrefPubMedGoogle Scholar
  • 8 Konno H, Tanaka T, Baba M et al. Quantitative analysis of vascular endothelial growth factor in colon cancer. Clinical and experimental. Eur Surg Res 1998; 30 (04) 273-278
    CrossrefPubMedGoogle Scholar
  • 9 Hatenbach EM, Olson TA, Goswitz JJ et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 1997; 121 (02) 169-175
    CrossrefPubMedGoogle Scholar
  • 10 Strohmeyer D, Strauss F, Rössing C et al. Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Anticancer Res 2004; 24 (3a) 1797-1804
    PubMedGoogle Scholar
  • 11 Maeda K, Chung YS, Ogawa Y et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996; 77 (05) 858-863
    CrossrefPubMedGoogle Scholar
  • 12 Feng Y, Wang W, Hu J et al. Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer. Anat Rec (Hoboken) 2010; 293 (05) 802-812
    CrossrefPubMedGoogle Scholar
  • 13 Xiang Z, Zeng Z, Tang Z et al. Increased expression of vascular endothelial growth factor-C and nuclear CXCR4 in hepatocellular carcinoma is correlated with lymph node metastasis and poor outcome. Cancer J 2009; 15 (06) 519-525
    CrossrefPubMedGoogle Scholar
  • 14 Morales-Gutiérrez C, Abad-Barahona A, Moreno-González E et al. Tumour VEGF/non tumour VEGF protein expression ration as a biomarker for survival in colorectal cancer patients. Eur J Surg Oncol 2011; 37 (06) 526-531
    CrossrefPubMedGoogle Scholar
  • 15 Valachis A, Polyzos NP, Patsopoulos NA et al. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 2010; 122 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 16 Yakes FM, Chen J, Tan J et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10 (12) 2298-2308
    CrossrefPubMedGoogle Scholar
  • 17 Klein M, Picard E, Vignaud JM et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 1999; 161 (01) 41-49
    CrossrefPubMedGoogle Scholar
  • 18 Turner HE, Harris AL, Melmed S et al. Angiogenesis in endocrine tumors. Endocr Rev 2003; 24 (05) 600-632
    CrossrefPubMedGoogle Scholar
  • 19 Capp C, Wajner SM, Siqueira DR et al. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 2010; 20 (08) 863-871
    CrossrefPubMedGoogle Scholar
  • 20 Erdem H, Gündogdu C, Sipal S. Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma. Exp Mol Pathol 2011; 90 (03) 312-317
    CrossrefPubMedGoogle Scholar
  • 21 Karaca Z, Tanriverdi F, Unluhizarci K et al. VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 2011; 164 (02) 277-284
    CrossrefPubMedGoogle Scholar
  • 22 Lennard CM, Patel A, Wilson J et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 2001; 129 (05) 552-558
    CrossrefPubMedGoogle Scholar
  • 23 Deshpande H, Roman S, Thumar J et al. Vandetanib (ZD6474) in the treatment of medullary thyroid cancer. Clin Med Insights Oncol 2011; 5: 213-221
    PubMedGoogle Scholar
  • 24 Mannavola D, Coco P, Vannucchi G et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007; 92 (09) 3531-3534
    CrossrefPubMedGoogle Scholar
  • 25 Brown RL. Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management. Target Oncol 2011; 6 (04) 217-226
    CrossrefPubMedGoogle Scholar
  • 26 Hsueh C, Lin JD, Wu IC et al. Vascular endothelial growth factors and angiopoietins in presentations and prognosis of papillary thyroid carcinoma. J Surg Oncol 2010; 103 (05) 395-399
    PubMedGoogle Scholar
  • 27 Bunone G, Vigneri P, Mariani L et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999; 155 (06) 1967-1976
    CrossrefPubMedGoogle Scholar
  • 28 Tanaka K, Kurebayashi J, Sonoo H et al. Expression of vascular endothelial growth factor family messenger RNA in diseased thyroid tissues. Surg Today 2002; 32 (09) 761-768
    CrossrefPubMedGoogle Scholar
  • 29 Itoh A, Iwase K, Jimbo S et al. Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders. World J Surg 2010; 34 (02) 242-248
    CrossrefPubMedGoogle Scholar
  • 30 Jebreel A, England J, Bedford K et al. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol 2007; 88 (04) 271-277
    CrossrefPubMedGoogle Scholar
  • 31 Sato K, Miyakawa M, Onoda N et al. Increased concentrations of vascular endothelial growth factor/vascular permeability factor in cyst fluid of enlarging and recurrent thyroid nodules. J Clin Endocrinol Metab 1997; 82 (06) 1968-1973
    CrossrefPubMedGoogle Scholar
  • 32 Vieira JM, Santos SC, Espadinha C et al. Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur J Endocrinol 2005; 153 (05) 701-709
    CrossrefPubMedGoogle Scholar
  • 33 Fan F, Wey JS, McCarty MF et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005; 24 (16) 2647-2653
    CrossrefPubMedGoogle Scholar
  • 34 Vaiman M, Nagibin A, Hagag P et al. Subtotal and near total versus total thyroidectomy for the management of multinodular goiter. World J Surg 2008; 32 (07) 1546-1551
    CrossrefPubMedGoogle Scholar
  • 35 Snook KL, Stalberg PL, Sidhu SB et al. Recurrence after total thyroidectomy for benign multinodular goiter. World J Surg 2007; 31 (03) 593-598
    CrossrefPubMedGoogle Scholar
  • 36 Moalem J, Suh I, Duh QY. Treatment and prevention of recurrence of multinodular goiter: an evidence-based review of the literature. World J Surg 2008; 32 (07) 1301-1312
    Google Scholar
  • 37 Basili G, Biagini C, Manetti A et al. Risk of recurrence following partial thyroidectomy for benign lesions. Report of 58 patients 15-25 years after surgery. Minerva Chir 2003; 58 (03) 321-329
    PubMedGoogle Scholar
  • 38 Iitaka M, Miura S, Yamanaka K et al. Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves’ disease and Hashimoto’s thyroiditis. J Clin Endocrinol Metab 1998; 83 (11) 3908-3912
    CrossrefPubMedGoogle Scholar
  • 39 Nagura S, Katoh R, Miyagi E et al. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density. Hum Pathol 2001; 32 (01) 10-17
    CrossrefPubMedGoogle Scholar
  • 40 Gérard AC, Denef JF, Many MC et al. Relationships between cell division, expression of growth factors and microcirculation in the thyroids of Tg-A2aR transgenic mice and patients with Graves’ disease. J Endocrinol 2003; 177 (02) 269-277
    CrossrefPubMedGoogle Scholar
  • 41 Sato S, Muraishi K, Tani J et al. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma. Endocr J 2010; 57 (19) 873-880
    CrossrefPubMedGoogle Scholar